NOUV.US Nouveau Life Pharmaceuticals Inc
- Market cap
- USD 666K
- P/E
- -
- P/B
- 22.72x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2025.
Is NOUV.US undervalued?
Graham numberThe Graham number of Nouveau Life Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nouveau Life Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Nouveau Life Pharmaceuticals Inc yet.
Nouveau Life Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nouveau Life Pharmaceuticals Inc
Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in providing a platform for remote senior care. The company also enables users to monitor patients in real time and access detailed patient information digitally; and its platform is designed to detect emergencies proactively and facilitate non-face-to-face care services. In addition, the company is developing robotic and artificial intelligence (AI)-based healthcare devices and wearables. The company w…
Full company profileNouveau Life Pharmaceuticals Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nouveau Life Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2002 | 2003 | 2004 | 2005 | 2006 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
| Operating Income | 180K | 229K | 318K | 267K | 357K | - | - | - | - | -17.2K | -22.5K |
| EBITDA | 180K | 229K | -200K | -213K | -214K | - | - | - | - | -17.2K | -22.5K |
| Net Income | -254K | -312K | -401K | -257K | -357K | - | - | - | - | -17.2K | -22.5K |
| EPS | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | - | - | - | - | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.25K | 7.91K | 946.00 | 29.0K | 1.33M | - | - | - | - | - | - |
| Total Liabilities | 800K | 848K | 961K | 898K | 1.01M | - | - | - | - | - | - |
| Shareholders' Equity | -799K | -840K | -960K | -869K | 316K | - | - | - | - | - | - |
| Cash & Short-term Investments | 1.25K | 7.91K | 946.00 | 3.53K | 3.97K | - | - | - | - | - | - |
| Total Debt | 238K | 244K | 297K | 47.3K | 67.8K | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.4K | -81.1K | -64.3K | -84.9K | -22.9K | - | - | - | - | - | -109K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | 0.00 |
| Free Cash Flow | -11.4K | -81.1K | -64.3K | -84.9K | -22.9K | - | - | - | - | - | - |
| Ratios | |||||||||||
| ROE | - | - | - | - | -113.1% | - | - | - | - | - | - |
| ROA | -20,368.5% | -3,949.0% | -42,434.6% | -884.6% | -26.9% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | 0.21x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nouveau Life Pharmaceuticals Inc dividends
Nouveau Life Pharmaceuticals Inc has not paid dividends in the last 5 fiscal years.
Who owns Nouveau Life Pharmaceuticals Inc
Ownership data of Nouveau Life Pharmaceuticals Inc is not available yet.
Nouveau Life Pharmaceuticals Inc company profile
- Company name
- Nouveau Life Pharmaceuticals Inc
- Ticker
- NOUV.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- December
- Address
- 3580 Wilshire Blvd, Los Angeles, CA, United States, 90010
- Phone
- 213 235 8554
- Website
- -
About Nouveau Life Pharmaceuticals Inc
Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in providing a platform for remote senior care. The company also enables users to monitor patients in real time and access detailed patient information digitally; and its platform is designed to detect emergencies proactively and facilitate non-face-to-face care services. In addition, the company is developing robotic and artificial intelligence (AI)-based healthcare devices and wearables. The company was formerly known as Gondwana Energy, Ltd. and changed its name to Nouveau Life Pharmaceuticals, Inc. in May 1998. The company was incorporated in 1998 and is based in Los Angeles, California. Nouveau Life Pharmaceuticals, Inc. operates as a subsidiary of Seniorgo.ai.
Nouveau Life Pharmaceuticals Inc management
5- Mr. Douglas DickieChief Financial Officer and Director · born 1947
- Mr. Brian ShibleyChairman of the Board, CEO & President
- Mr. Darcy PennerManager of Investor Relations
- Mr. Rolly HeinActing Vice President and Director · born 1944
- Mr. Warren WheelerTreasurer, Secretary and Director